# Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

> **NCT02484716** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 58 (actual)

## Conditions studied

- Telangiectasia, Hereditary Hemorrhagic
- Osler Rendu Disease

## Interventions

- **DRUG:** Timolol nasal spray
- **DRUG:** Placebo nasal spray

## Key facts

- **NCT ID:** NCT02484716
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-11
- **Final completion:** 2018-01-29
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484716, "Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02484716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*